Validation of a stroke model in rat compatible with rt-PA-induced thrombolysis: new hope for successful translation to the clinic.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 07 2020
22 07 2020
Historique:
received:
22
01
2020
accepted:
29
06
2020
entrez:
24
7
2020
pubmed:
24
7
2020
medline:
17
12
2020
Statut:
epublish
Résumé
The recent clinical trial (DAWN) suggests that recanalization treatment may be beneficial up to 24 h after stroke onset, thus re-opening avenues for development of new therapeutic strategies. Unfortunately, there is a continuous failure of drugs in clinical trials and one of the major reasons proposed for this translational roadblock is the animal models. Therefore, the purpose of this study was to validate a new thromboembolic stroke rat model that mimics the human pathology, and that can be used for evaluating new strategies to save the brain in conditions compatible with recanalization. Stroke was induced by injection of thrombin into the middle cerebral artery. Recombinant tissue-type plasminogen activator (rt-PA) or saline was administrated at 1 h/4 h after stroke onset, and outcome was evaluated after 24 h. Induced ischemia resulted in reproducible cortical brain injuries causing a decrease in neurological function 24 h after stroke onset. Early rt-PA treatment resulted in recanalization, reduced infarct size and improved neurological functions, while late rt-PA treatment showed no beneficial effects and caused hemorrhagic transformation in 25% of the rats. This validated and established model's resemblance to human ischemic stroke and high translational potential, makes it an important tool in the development of new therapeutic strategies for stroke.
Identifiants
pubmed: 32699371
doi: 10.1038/s41598-020-69081-0
pii: 10.1038/s41598-020-69081-0
pmc: PMC7376012
doi:
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12191Références
Luengo-Fernandez, R., Violato, M., Candio, P. & Leal, J. Economic burden of stroke across Europe: A population-based cost analysis. Eur. Stroke J. https://doi.org/10.1177/2396987319883160 (2019).
doi: 10.1177/2396987319883160
pubmed: 32232167
pmcid: 7092742
Collaborators, G. B. D. S. Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18, 439–458. https://doi.org/10.1016/S1474-4422(19)30034-1 (2019).
doi: 10.1016/S1474-4422(19)30034-1
Chia, N. H., Leyden, J. M., Newbury, J., Jannes, J. & Kleinig, T. J. Determining the number of ischemic strokes potentially eligible for endovascular thrombectomy: A population-based study. Stroke J. Cereb. Circ. 47, 1377–1380. https://doi.org/10.1161/STROKEAHA.116.013165 (2016).
doi: 10.1161/STROKEAHA.116.013165
Bhatia, R. et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: Real-world experience and a call for action. Stroke J. Cereb. Circ. 41, 2254–2258. https://doi.org/10.1161/STROKEAHA.110.592535 (2010).
doi: 10.1161/STROKEAHA.110.592535
Lee, K. Y. et al. Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients. Stroke J. Cereb. Circ. 38, 192–193. https://doi.org/10.1161/01.STR.0000251788.03914.00 (2007).
doi: 10.1161/01.STR.0000251788.03914.00
Saver, J. L. et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N. Engl. J. Med. 372, 2285–2295. https://doi.org/10.1056/NEJMoa1415061 (2015).
doi: 10.1056/NEJMoa1415061
pubmed: 25882376
McMeekin, P. et al. Estimating the number of UK stroke patients eligible for endovascular thrombectomy. Eur. Stroke J. 2, 319–326. https://doi.org/10.1177/2396987317733343 (2017).
doi: 10.1177/2396987317733343
pubmed: 29900409
pmcid: 5992738
Tsivgoulis, G. et al. Eligibility for mechanical thrombectomy in acute ischemic stroke: A phase IV multi-center screening log registry. J. Neurol. Sci. 371, 96–99. https://doi.org/10.1016/j.jns.2016.10.018 (2016).
doi: 10.1016/j.jns.2016.10.018
pubmed: 27871458
Tanne, D. et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey. Circulation 105, 1679–1685. https://doi.org/10.1161/01.cir.0000012747.53592.6a (2002).
doi: 10.1161/01.cir.0000012747.53592.6a
pubmed: 11940547
National Institute of Neurological, D. & Stroke rt, P. A. S. S. G. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333, 1581–1587. https://doi.org/10.1056/NEJM199512143332401 (1995).
doi: 10.1056/NEJM199512143332401
O’Collins, V. E. et al. 1,026 experimental treatments in acute stroke. Ann. Neurol. 59, 467–477. https://doi.org/10.1002/ana.20741 (2006).
doi: 10.1002/ana.20741
pubmed: 16453316
Benjamin, E. J. et al. Heart disease and stroke statistics-2018 update: A report from the American Heart Association. Circulation 137, e67–e492. https://doi.org/10.1161/CIR.0000000000000558 (2018).
doi: 10.1161/CIR.0000000000000558
pubmed: 29386200
Hossmann, K. A. The two pathophysiologies of focal brain ischemia: Implications for translational stroke research. J. Cereb. Blood Flow Metab. 32, 1310–1316. https://doi.org/10.1038/jcbfm.2011.186 (2012).
doi: 10.1038/jcbfm.2011.186
pubmed: 22234335
pmcid: 3390813
Kilic, E., Hermann, D. M. & Hossmann, K. A. A reproducible model of thromboembolic stroke in mice. NeuroReport 9, 2967–2970. https://doi.org/10.1097/00001756-199809140-00009 (1998).
doi: 10.1097/00001756-199809140-00009
pubmed: 9804299
Zhang, Z. et al. A new rat model of thrombotic focal cerebral ischemia. J. Cereb. Blood Flow Metab. 17, 123–135. https://doi.org/10.1097/00004647-199702000-00001 (1997).
doi: 10.1097/00004647-199702000-00001
pubmed: 9040491
Rasmussen, R. S., Overgaard, K., Pakola, S. & Boysen, G. Effects of microplasmin on recovery in a rat embolic stroke model. Neurol. Res. 30, 75–81. https://doi.org/10.1179/016164107X181860 (2008).
doi: 10.1179/016164107X181860
pubmed: 17588313
Orset, C., Haelewyn, B., Vivien, K., Vivien, D. & Young, A. R. In Rodent Models of Stroke (ed. Ulrich Dirnagl) 55–70 (Humana Press, Totowa, 2010).
Macrae, I. M. Preclinical stroke research—advantages and disadvantages of the most common rodent models of focal ischaemia. Br. J. Pharmacol. 164, 1062–1078. https://doi.org/10.1111/j.1476-5381.2011.01398.x (2011).
doi: 10.1111/j.1476-5381.2011.01398.x
pubmed: 21457227
pmcid: 3229752
Kaneko, D., Nakamura, N. & Ogawa, T. Cerebral infarction in rats using homologous blood emboli: Development of a new experimental model. Stroke J. Cereb. Circ. 16, 76–84 (1985).
doi: 10.1161/01.STR.16.1.76
Kudo, M., Aoyama, A., Ichimori, S. & Fukunaga, N. An animal model of cerebral infarction. Homologous blood clot emboli in rats. Stroke J. Cereb. Circ. 13, 505–508 (1982).
doi: 10.1161/01.STR.13.4.505
Wang, C. X., Todd, K. G., Yang, Y., Gordon, T. & Shuaib, A. Patency of cerebral microvessels after focal embolic stroke in the rat. J. Cereb. Blood Flow Metab. 21, 413–421. https://doi.org/10.1097/00004647-200104000-00010 (2001).
doi: 10.1097/00004647-200104000-00010
pubmed: 11323527
Orset, C. et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke J. Cereb. Circ. 38, 2771–2778. https://doi.org/10.1161/strokeaha.107.487520 (2007).
doi: 10.1161/strokeaha.107.487520
Orset, C. et al. Efficacy of alteplase in a mouse model of acute ischemic stroke: A retrospective pooled analysis. Stroke J. Cereb. Circ. 47, 1312–1318. https://doi.org/10.1161/STROKEAHA.116.012238 (2016).
doi: 10.1161/STROKEAHA.116.012238
Campos, F. et al. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model. Stroke J. Cereb. Circ. 44, 505–511. https://doi.org/10.1161/STROKEAHA.112.679043 (2013).
doi: 10.1161/STROKEAHA.112.679043
Garcia-Yebenes, I. et al. A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke. Stroke J. Cereb. Circ. 42, 196–203. https://doi.org/10.1161/strokeaha.110.600452 (2011).
doi: 10.1161/strokeaha.110.600452
Langhauser, F. L. et al. Thromboembolic stroke in C57BL/6 mice monitored by 9.4 T MRI using a 1H cryo probe. Exp. Transl. Stroke Med. 4, 18. https://doi.org/10.1186/2040-7378-4-18 (2012).
doi: 10.1186/2040-7378-4-18
pubmed: 22967955
pmcid: 3514176
Encarnacion, A. et al. Long-term behavioral assessment of function in an experimental model for ischemic stroke. J. Neurosci. Methods 196, 247–257. https://doi.org/10.1016/j.jneumeth.2011.01.010 (2011).
doi: 10.1016/j.jneumeth.2011.01.010
pubmed: 21256866
pmcid: 3539723
Boltze, J. et al. The stairway: A novel behavioral test detecting sensomotoric stroke deficits in rats. Artif. Organs 30, 756–763. https://doi.org/10.1111/j.1525-1594.2006.00297.x (2006).
doi: 10.1111/j.1525-1594.2006.00297.x
pubmed: 17026574
Kleim, J. A., Boychuk, J. A. & Adkins, D. L. Rat models of upper extremity impairment in stroke. ILAR J. 48, 374–384 (2007).
doi: 10.1093/ilar.48.4.374
del Zoppo, G. J. et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann. Neurol. 32, 78–86. https://doi.org/10.1002/ana.410320113 (1992).
doi: 10.1002/ana.410320113
pubmed: 1642475
Di Cera, E., Dang, Q. D. & Ayala, Y. M. Molecular mechanisms of thrombin function. Cell Mol. Life Sci. 53, 701–730 (1997).
doi: 10.1007/s000180050091
Saqqur, M. et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke J. Cereb. Circ. 38, 948–954. https://doi.org/10.1161/01.STR.0000257304.21967.ba (2007).
doi: 10.1161/01.STR.0000257304.21967.ba
Broussalis, E. et al. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. Drug Discov. Today 17, 671–684. https://doi.org/10.1016/j.drudis.2012.02.011 (2012).
doi: 10.1016/j.drudis.2012.02.011
pubmed: 22405898
Durukan, A. & Tatlisumak, T. Acute ischemic stroke: Overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol. Biochem. Behav. 87, 179–197. https://doi.org/10.1016/j.pbb.2007.04.015 (2007).
doi: 10.1016/j.pbb.2007.04.015
pubmed: 17521716
Rasmussen, R. S., Overgaard, K., Hildebrandt-Eriksen, E. S. & Boysen, G. D-Amphetamine improves cognitive deficits and physical therapy promotes fine motor rehabilitation in a rat embolic stroke model. Acta Neurol. Scand. 113, 189–198. https://doi.org/10.1111/j.1600-0404.2005.00547.x (2006).
doi: 10.1111/j.1600-0404.2005.00547.x
pubmed: 16441250
Overgaard, K., Rasmussen, R. S. & Johansen, F. F. The site of embolization related to infarct size, oedema and clinical outcome in a rat stroke model—further translational stroke research. Exp. Transl. Stroke Med. 2, 17. https://doi.org/10.1186/2040-7378-2-17 (2010).
doi: 10.1186/2040-7378-2-17
pubmed: 20849633
pmcid: 2949733
Drieu, A. et al. Immune responses and anti-inflammatory strategies in a clinically relevant model of thromboembolic ischemic stroke with reperfusion. Transl. Stroke Res. https://doi.org/10.1007/s12975-019-00733-8 (2019).
doi: 10.1007/s12975-019-00733-8
pubmed: 31522409
Roberts, L. & Counsell, C. Assessment of clinical outcomes in acute stroke trials. Stroke J. Cereb. Circ. 29, 986–991 (1998).
doi: 10.1161/01.STR.29.5.986
Hill, M. D., Buchan, A. M. & Canadian Alteplase for Stroke Effectiveness Study, I. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172, 1307–1312. https://doi.org/10.1503/cmaj.1041561 (2005).
doi: 10.1503/cmaj.1041561
pubmed: 15883405
pmcid: 557101
Hacke, W. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317–1329. https://doi.org/10.1056/NEJMoa0804656 (2008).
doi: 10.1056/NEJMoa0804656
pubmed: 18815396
Cho, T. H. et al. Reperfusion within 6 hours outperforms recanalization in predicting penumbra salvage, lesion growth, final infarct, and clinical outcome. Stroke J. Cereb. Circ. 46, 1582–1589. https://doi.org/10.1161/STROKEAHA.114.007964 (2015).
doi: 10.1161/STROKEAHA.114.007964
Ueno, T. et al. Association of survival and hyperthermia after rt-PA for ischemic stroke. Acta Neurol. Scand. 138, 574–578. https://doi.org/10.1111/ane.13011 (2018).
doi: 10.1111/ane.13011
pubmed: 30091238
Noor, R., Wang, C. X. & Shuaib, A. Hyperthermia masks the neuroprotective effects of tissue plaminogen activator. Stroke J. Cereb. Circ. 36, 665–669. https://doi.org/10.1161/01.STR.0000155684.20864.58 (2005).
doi: 10.1161/01.STR.0000155684.20864.58
Garcia-Culebras, A. et al. Toll-like receptor 4 mediates hemorrhagic transformation after delayed tissue plasminogen activator administration in in situ thromboembolic stroke. Stroke J. Cereb. Circ. 48, 1695–1699. https://doi.org/10.1161/STROKEAHA.116.015956 (2017).
doi: 10.1161/STROKEAHA.116.015956
Dijkhuizen, R. M., Asahi, M., Wu, O., Rosen, B. R. & Lo, E. H. Delayed rt-PA treatment in a rat embolic stroke model: Diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging. J. Cereb. Blood Flow Metab. 21, 964–971. https://doi.org/10.1097/00004647-200108000-00009 (2001).
doi: 10.1097/00004647-200108000-00009
pubmed: 11487732
Clark, W. M., Albers, G. W., Madden, K. P. & Hamilton, S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): Results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke J. Cereb. Circ. 31, 811–816. https://doi.org/10.1161/01.str.31.4.811 (2000).
doi: 10.1161/01.str.31.4.811
Nogueira, R. G. et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N. Engl. J. Med. 378, 11–21. https://doi.org/10.1056/NEJMoa1706442 (2018).
doi: 10.1056/NEJMoa1706442
pubmed: 29129157
Korninger, C. & Collen, D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 46, 561–565 (1981).
doi: 10.1055/s-0038-1653411
Tomkins, A. J., Hood, R. J., Levi, C. R. & Spratt, N. J. Tissue Plasminogen Activator for preclinical stroke research: Neither “rat” nor “human” dose mimics clinical recanalization in a carotid occlusion model. Sci. Rep. 5, 16026. https://doi.org/10.1038/srep16026 (2015).
doi: 10.1038/srep16026
pubmed: 26522691
pmcid: 4629197
Haelewyn, B., Risso, J. J. & Abraini, J. H. Human recombinant tissue-plasminogen activator (alteplase): Why not use the “human” dose for stroke studies in rats?. J. Cereb. Blood Flow Metab. 30, 900–903. https://doi.org/10.1038/jcbfm.2010.33 (2010).
doi: 10.1038/jcbfm.2010.33
pubmed: 20216551
pmcid: 2949192